These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21515524)

  • 1. Effect of withdrawing topical fusidic acid on Staphylococcus aureus resistance rates.
    Wylie G; Dancer SJ; Bilsland D
    Scott Med J; 2011 Feb; 56(1):10-1. PubMed ID: 21515524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of fusidic acid-resistant Staphylococcus aureus despite restrictions on antibiotic use.
    Mitra A; Mohanraj M; Shah M
    Clin Exp Dermatol; 2009 Mar; 34(2):136-9. PubMed ID: 18828847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Increase in rate of resistance to fusidic acid among Staphylococcus aureus isolates from patients admitted with atopic dermatitis].
    Peeters KA; Mascini EM; Blok HE; Sanders CJ
    Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2100-1. PubMed ID: 12448968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use.
    Sule O; Brown NM; Willocks LJ; Day J; Shankar S; Palmer CR; Burrows NP
    Int J Antimicrob Agents; 2007 Jul; 30(1):78-82. PubMed ID: 17475448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
    Howden BP; Grayson ML
    Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staphylococcus aureus and topical fusidic acid use: results of a clinical audit on antimicrobial resistance.
    Heng YK; Tan KT; Sen P; Chow A; Leo YS; Lye DC; Chan RK
    Int J Dermatol; 2013 Jul; 52(7):876-81. PubMed ID: 23432159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis.
    Alsterholm M; Flytström I; Bergbrant IM; Faergemann J
    Acta Derm Venereol; 2010; 90(1):52-7. PubMed ID: 20107726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Outburst of fusidic acid resistant Staphylococcus aureus].
    Kanazaki H; Akiyama H; Kanamoto A; Abe Y; Yamada T; Arata J; Umemura S; Ikeda M
    Nihon Hifuka Gakkai Zasshi; 1989 Apr; 99(4):507-10. PubMed ID: 2614994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Increase in rate of resistance to fusidic acid among Staphylococcus aureus isolates from patients admitted with atopic dermatitis].
    Koning S; Thomas S; van der Wouden JC
    Ned Tijdschr Geneeskd; 2003 Jan; 147(3):134; author reply 135. PubMed ID: 12577775
    [No Abstract]   [Full Text] [Related]  

  • 10. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale.
    Williamson DA; Monecke S; Heffernan H; Ritchie SR; Roberts SA; Upton A; Thomas MG; Fraser JD
    Clin Infect Dis; 2014 Nov; 59(10):1451-4. PubMed ID: 25139961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impetigo in a population over 8.5 years: incidence, fusidic acid resistance and molecular characteristics.
    Rørtveit S; Skutlaberg DH; Langeland N; Rortveit G
    J Antimicrob Chemother; 2011 Jun; 66(6):1360-4. PubMed ID: 21393202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients.
    Shah M; Mohanraj M
    Br J Dermatol; 2003 May; 148(5):1018-20. PubMed ID: 12786835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France.
    Laurent F; Tristan A; Croze M; Bes M; Meugnier H; Lina G; Vandenesch F; Etienne J
    J Antimicrob Chemother; 2009 Feb; 63(2):420-1; author reply 421. PubMed ID: 18978362
    [No Abstract]   [Full Text] [Related]  

  • 14. Staphylococcus aureus elongation factor G--structure and analysis of a target for fusidic acid.
    Chen Y; Koripella RK; Sanyal S; Selmer M
    FEBS J; 2010 Sep; 277(18):3789-803. PubMed ID: 20718859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).
    Castanheira M; Watters AA; Mendes RE; Farrell DJ; Jones RN
    J Antimicrob Chemother; 2010 Jul; 65(7):1353-8. PubMed ID: 20430787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections.
    Hurdle JG; O'Neill AJ; Chopra I
    J Antimicrob Chemother; 2004 Aug; 54(2):549-52. PubMed ID: 15243028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusidic acid resistance in Staphylococcus aureus isolates.
    Brown EM; Thomas P
    Lancet; 2002 Mar; 359(9308):803. PubMed ID: 11888633
    [No Abstract]   [Full Text] [Related]  

  • 18. Fusidic acid resistance, mediated by fusB, in bovine coagulase-negative staphylococci.
    Yazdankhah SP; Asli AW; Sørum H; Oppegaard H; Sunde M
    J Antimicrob Chemother; 2006 Dec; 58(6):1254-6. PubMed ID: 17060340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus.
    Besier S; Ludwig A; Brade V; Wichelhaus TA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1426-31. PubMed ID: 15793122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusidic acid resistant Staphylococcus aureus and skin disease.
    Lomholt HB
    Acta Derm Venereol; 2010; 90(1):4. PubMed ID: 20107716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.